共 23 条
- [22] TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
- [23] Fatty acid synthase (FAS) inhibitor C75 induces hyperactivation of ERK1/2 MAPK-estrogen receptor alpha (ER-alpha) cross-talk, loss of ER-alpha expression, inhibition of cell growth, and apoptotic cell death in hormone-dependent breast cancer cells. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6107S - 6108S